KIT and gastrointestinal stromal tumor: Targeted therapy with tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of GIST, with imatinib approved for patients with KIT positive unresectable and/or metastatic malignant GIST, sunitinib for those with imatinib-resistant GIST and regorafenib for patients with imatinib- and sunitinib-resistant GIST [3].